-
公开(公告)号：US20170246347A1
公开(公告)日：2017-08-31
申请号：US15588460
申请日：2017-05-05
Inventor： Arturo J. Vegas , Joshua C. Doloff , Omid Veiseh , Robert S. Langer , Daniel G. Anderson
IPC: A61L27/34 , A61L27/38 , A61K9/00 , A61L27/16 , A61K38/02 , A61L27/10 , A61L27/04 , A61K35/36 , A61K35/12 , A61L27/54 , A61L27/18
CPC classification number: A61L27/3804 , A61K9/0051 , A61K35/12 , A61K35/36 , A61K35/39 , A61K38/02 , A61K2035/128 , A61L27/04 , A61L27/10 , A61L27/16 , A61L27/18 , A61L27/20 , A61L27/34 , A61L27/3813 , A61L27/3839 , A61L27/54 , A61L27/56 , A61L29/14 , A61L2300/252 , A61L2300/254 , A61L2400/18 , C08J7/12
Abstract: Products, such as devices, prostheses, and materials, whose surfaces have been modified in order to impart beneficial properties to these products are disclosed. The surface-modified products have improved biocompatibility compared to a corresponding product that lacks the modification. Following implantation in a subject, the surface-modified products induce a lower foreign-body response, compared to a corresponding unmodified product.
-
公开(公告)号：US20170239190A1
公开(公告)日：2017-08-24
申请号：US15588481
申请日：2017-05-05
Applicant: Massachusetts Institute of Technology
Inventor： Arturo J. Vegas , Minglin Ma , Kaitlin M. Bratlie , Daniel G. Anderson , Robert S. Langer
CPC classification number: A61K9/5036 , A61K9/0024 , A61K9/5161 , A61K35/39 , A61K45/06 , C08B37/0084
Abstract: Covalently modified alginate polymers, possessing enhanced biocompatibility and tailored physiochemical properties, as well as methods of making and use thereof, are disclosed herein. The covalently modified alginates are useful as a matrix for the encapsulation and transplantation of cells. Also disclosed are high throughput methods for the characterizing the biocompatibility and physiochemical properties of modified alginate polymers.
-
公开(公告)号：US20170079916A1
公开(公告)日：2017-03-23
申请号：US15274954
申请日：2016-09-23
Inventor： Omar F. Khan , Jasdave S. Chahal , Daniel G. Anderson , Hidde Ploegh , Robert S. Langer
IPC: A61K9/14 , A61K31/713 , A61K39/00 , A61K49/00
Abstract: Compositions and methods for modified dendrimer nanoparticle (“MDNP”) delivery of therapeutic, prophylactic and/or diagnostic agent such as large repRNA molecules to the cells of a subject have been developed. MDNPs efficiently drive proliferation of antigen-specific T cells against intracellular antigen, and potentiate antigen-specific antibody responses. MDNPs can be multiplexed to deliver two or more different repRNAs to modify expression kinetics of encoded antigens and to simultaneous deliver repRNAs and mRNAs including the same UTR elements that promote expression of encoded antigens.
-
公开(公告)号：US20170015994A1
公开(公告)日：2017-01-19
申请号：US15121292
申请日：2015-02-24
Applicant: MASSACHUSETTS INSTITUTE OF TECHNOLOGY
Inventor： Daniel G. Anderson , Hao Yin , Roman L. Bogorad , Tyler E. Jacks , Wen Xue
IPC: C12N15/10 , A61K31/713 , A61K9/00
CPC classification number: C12N15/1024 , A61K9/0019 , A61K31/713 , C12N15/102 , C12N15/63
Abstract: Methods of transfecting cells in vivo, by administering an injectable pharmaceutical composition including a genome editing composition and a pharmaceutically acceptable carrier to a subject by hydrodynamic injection into a vessel of the subject are disclosed. Typically, the pharmaceutical composition is administered in a volume and at rate of injection suitable to transfect target eukaryotic cells in the subject with an effective amount of the genome editing composition to alter the genome of the target cells. In preferred embodiments the subject is a mammal, such as rodent, or a primate such as a human. The methods can be used to treat one or more symptoms of a genetic disease or condition.
Abstract translation: 公开了通过向受试者施用包含基因组编辑组合物和药学上可接受的载体的可注射药物组合物在体内转染细胞的方法，通过流体动力学注射到受试者的血管中。 通常，药物组合物以体积和注射速率施用，适合于用有效量的基因组编辑组合物转染受试者中的靶真核细胞以改变靶细胞的基因组。 在优选的实施方案中，受试者是哺乳动物，例如啮齿动物，或灵长类动物例如人。 该方法可用于治疗遗传性疾病或病症的一种或多种症状。
-
公开(公告)号：US20160030360A1
公开(公告)日：2016-02-04
申请号：US14817084
申请日：2015-08-03
Applicant: Massachusetts Institute of Technology
Inventor： Arturo J. Vegas , Joshua C. Doloff , Omid Veiseh , Minglin Ma , Robert S. Langer , Daniel G. Anderson
CPC classification number: A61K9/5036 , A61K9/0024 , A61K35/39 , A61L29/085 , A61L31/10 , A61L33/08 , C08B37/0084 , C12N5/0012 , C12N5/0677 , C08L5/04
Abstract: Covalently modified alginate polymers, possessing enhanced biocompatibility and tailored physiochemical properties, as well as methods of making and use thereof, are disclosed herein. The covalently modified alginates are useful as a matrix for coating of any material where reduced fibrosis is desired, such as encapsulated cells for transplantation and medical devices implanted or used in the body.
Abstract translation: 本文公开了具有增强的生物相容性和定制的理化性质的共价改性的藻酸盐聚合物，以及其制备和使用方法。 共价修饰的藻酸盐可用作涂覆需要减少纤维化的任何材料的基质，例如用于移植的包封细胞和植入或用于体内的医疗装置。
-
Patent Agency Ranking
76.发明申请Multi-Layer Hydrogel Capsules for Encapsulation of Cells and Cell Aggregates 审中-公开用于包封细胞和细胞聚集体的多层水凝胶胶囊公开(公告)号：US20160030359A1
公开(公告)日：2016-02-04
申请号：US14776639
申请日：2014-03-14
Applicant: MASSACHUSETTS INSTITUTE OF TECHNOLOGY
Inventor： Minglin Ma , Daniel G. Anderson , Robert S. Langer , Omid Veiseh , Joshua Charles Doloff , Delai Chen , Christian J. Kastrup , Arturo Jose Vegas
CPC classification number: A61K9/0024 , A61K9/4833 , A61K9/4866 , A61K9/5036 , A61K9/5078 , A61K9/5089 , A61K35/39 , A61K45/06 , A61K2035/126
Abstract: Biomedical devices for implantation with decreased pericapsular fibrotic overgrowth are disclosed. The device includes biocompatible materials and has specific characteristics that allow the device to elicit less of a fibrotic reaction after implantation than the same device lacking one or more of these characteristic that are present on the device. Biocompatible hydrogel capsules encapsulating mammalian cells having a diameter of greater than 1 mm, and optionally a cell free core, are disclosed which have reduced fibrotic overgrowth after implantation in a subject. Methods of treating a disease in a subject are also disclosed that involve administering a therapeutically effective amount of the disclosed encapsulated cells to the subject.
Abstract translation: 公开了用于植入具有减少的pericapsular纤维化过度生长的生物医学装置。 该装置包括生物相容性材料并且具有允许装置在植入之后引起较少的纤维化反应的特性，而不是缺乏装置中存在的这些特征中的一种或多种的相同装置。 公开了包封直径大于1mm的哺乳动物细胞和任选的无细胞核的生物相容性水凝胶胶囊，其在植入受试者后具有减少的纤维化过度生长。 还公开了治疗受试者疾病的方法，其涉及向受试者施用治疗有效量的所公开的封闭细胞。
-
公开(公告)号：US09236556B2
公开(公告)日：2016-01-12
申请号：US14071482
申请日：2013-11-04
Inventor： Mingming Ma , Liang Guo , Daniel G. Anderson , Omid C. Farokhzad , Robert S. Langer
IPC: C08J3/075 , H01L41/193 , H01L41/37 , C08K5/55 , C08L65/00
CPC classification number: H01L41/193 , C08G2210/00 , C08G2261/3221 , C08G2261/44 , C08J3/075 , C08J2371/02 , C08J2465/00 , C08K3/38 , C08K5/053 , C08L65/00 , C08L71/02 , H01L41/37
Abstract: Water-responsive composite materials are provided containing a polymeric matrix and a water-responsive gel integrated into the polymeric matrix. The water-responsive gel can include a polyol or an alkoxylated polyol crosslinked by reversibly hydrolysable bonds, such as borate ester bonds. The polymeric matrix can include conjugated polymers such as poly(pyrrole) containing polymers. The composite material is capable of rapid actuation in the presence of a water gradient and can exhibit power densities greater than 1 W/kg. Methods of making water-responsive composite materials are provided, including by electropolymerization. Devices containing water-responsive composite materials are provided for sensing, locomotion, and power generation.
Abstract translation: 提供了水反应性复合材料，其包含聚合物基质和整合到聚合物基质中的水响应性凝胶。 水反应性凝胶可以包括通过可逆水解的键如硼酸酯键交联的多元醇或烷氧基化多元醇。 聚合物基质可以包括共轭聚合物，例如含聚（吡咯）的聚合物。 复合材料能够在水梯度的存在下快速致动，并且可以显示大于1W / kg的功率密度。 提供制备水响应复合材料的方法，包括通过电聚合。 提供含水响应复合材料的设备用于感测，运动和发电。
-
公开(公告)号：US12163124B2
公开(公告)日：2024-12-10
申请号：US17195625
申请日：2021-03-08
Applicant: Massachusetts Institute of Technology
Inventor： Hao Yin , Wen Xue , Daniel G. Anderson , Joseph R. Dorkin , Tyler E. Jacks
Abstract: The present disclosure relates to compositions and methods for modifying a gene sequence, and for systems for delivering such compositions. For example, the disclosure relates to modifying a gene sequence using a CRISPR-Cas9 or other nucleic acid editing system, and methods and delivery systems for achieving such gene modification, such as viral or non-viral delivery systems.
-
公开(公告)号：US20240271158A1
公开(公告)日：2024-08-15
申请号：US18607256
申请日：2024-03-15
Applicant: Massachusetts Institute of Technology
Inventor： Daniel G. Anderson , Robert Alexander Wesselhoeft , Piotr S. Kowalski
CPC classification number: C12N15/85 , C07K16/2803 , C12N15/11 , C07K2317/31 , C12N2015/8518 , C12N2015/859 , C12N2800/107 , C12N2800/202 , C12N2800/70 , C12N2840/203 , C12N2840/55 , C12N2840/60 , C12N2999/007
Abstract: Circular RNA and methods and constructs for engineering circular RNA are disclosed. In some embodiments, the circular RNA includes the following elements arranged in the following sequence: a) an adjacent exon sequence of a 3′ Group I self-splicing intron-exon, b) an internal ribosome entry site (IRES), c) a protein coding region or noncoding region, and d) an adjacent exon sequence of a 5′ Group I self-splicing intron-exon.
-
公开(公告)号：US20240158807A1
公开(公告)日：2024-05-16
申请号：US18544160
申请日：2023-12-18
Applicant: Massachusetts Institute of Technology
Inventor： Daniel G. Anderson , Robert Alexander Wesselhoeft , Piotr S. Kowalski
CPC classification number: C12N15/85 , C07K16/2803 , C12N15/11 , C07K2317/31 , C12N2015/8518 , C12N2015/859 , C12N2800/107 , C12N2800/202 , C12N2800/70 , C12N2840/203 , C12N2840/55 , C12N2840/60 , C12N2999/007
Abstract: Circular RNA and methods and constructs for engineering circular RNA are disclosed. In some embodiments, the circular RNA includes the following elements arranged in the following sequence: a) a 3′ Group I self-splicing intron fragment, b) an internal ribosome entry site (IRES), c) a protein coding region or noncoding region, and d) a 5′ Group I self-splicing intron fragment.
-
-
-
-
-
-
-
-
-
Search Results
104
records
(took 0.041 seconds)
